The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Seagen; Veru
Consulting or Advisory Role - MyCareGorithm
Travel, Accommodations, Expenses - A2Bio
 
Ines Verdon
Employment - Rubius Therapeutics; Turnstone Bio
Stock and Other Ownership Interests - Gilead Sciences; Iovance Biotherapeutics; Sierra Oncology
 
Maclean Hall
Stock and Other Ownership Interests - Abbvie; Amgen; Biohaven Pharmaceuticals; Bristol Myers Squibb; CVS Health; Elevance Health; Microsoft; Omega Healthcare Investors; SABRA Health REIT; UnitedHealthcare
Research Funding - Iovance Biotherapeutics; Turnstone Bio
Patents, Royalties, Other Intellectual Property - Moffitt Cancer Center has licensed Intellectual Property related to the proliferation and expansion of tumor-infiltrating lymphocytes (TIL) to Iovance Biotherapeutics. I am a co-inventor on such Intellectual Property.
 
Shari Pilon-Thomas
Consulting or Advisory Role - KSQ Therapeutics; Morphogenesis, Inc.
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Dyve Biosciences (Inst); Intellia Therapeutics (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - IP licensed from Moffitt to Tuhura. (Inst); Moffitt Cancer Center has licensed Intellectual Property related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Shari Pilon-Thomas is an inventor on such Intellectual Property. (Inst); Patent with Provectus (Inst)
 
Guilherme Rabinowits
Consulting or Advisory Role - BioMedical Insights; BostonGene; Exelixis; Merck Serono; replimune; Sanofi/Regeneron
 
Christine H. Chung
Consulting or Advisory Role - AVEO; Exelixis; Fulgent Pharma; Genmab; Seagen